Key inclusion criteria for phase 2:
- Children and adolescents between 0 and 21 years of age with a locally advanced or metastatic IF with a positive ETS gene variation 6 (ETV6) detected by FISH or by molecular analysis.
- Children and adolescents between 0 and 21 years of age with a locally advanced solid tumor or a primary CNS tumor with proven NTRK gene fusion
- At least one measurable lesion according to RECIST or RANO
- Karnofsky or Lansky > 50
For more information, see the study registry: The study is registered with the "U.S. National Institutes of Health" (ClinicalTrials.gov).
See NCT02637687
EudraCT-Number: 2016-003498-16